| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 47(3); 2015 > Article
Kim, Lee, Choi, Shin, Kim, Cho, Lee, and Park: Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma


We report a case of a 56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-cell lymphoma with a BRCA1 gene mutation. Evidence is mounting that there is a large increase in the risk for hematologic malignancies among patients with genetic changes in the BRCA pathways. The genomic analysis demonstrated a frameshift mutation in the BRCA1 gene: 277_279delinsCC (Phe93fs). It is a novel BRCA1 mutation that has never been reported, and caused malignant lymphoma as well as breast and ovarian cancer.


Breast cancer is the second most common cancer in Korean women and is expected to continually increase [1]. Hereditary breast cancer accounts for 5%-10% of total cases. Most hereditary breast cancers are associated with mutations in the BRCA1 and BRCA2 genes [2], which confer high susceptibility to familial breast and/or ovarian cancer [3,4].
Associated with hereditary breast/ovarian cancer, the BRCA1 is the most extensively studied cancer susceptibility gene. Germline mutations of BRCA1 gene result in a predisposition for developing early-onset breast and ovarian cancer with penetrance as high as 85% and 65%, respectively [5]. The protein products of the BRCA1 gene regulate, at least in part, transcriptional activation, DNA repair, cell-cycle checkpoint control and chromosomal remodeling [6]. About 1,500 genetic variants of BRCA1 are described in the Breast Cancer Information Core (BIC). A recent meta-analysis reported a large increase in the risk for hematologic malignancies among patients with the genetic changes in BRCA pathways [7].
We report a case of a 56-year-old woman with breast cancer, ovarian cancer and diffuse large B-cell lymphoma with a novel BRCA1 gene mutation that has never been reported.

Case Report

A 56-year-old woman was referred to Korea University Anam Hospital for further management for recurred ovarian cancer. The patient was diagnosed with invasive ductal carcinoma in the left breast in 2005 (Fig. 1A). She had undergone modified radical mastectomy and axillary lymph node dissection. A right adrenal mass was incidentally found during staging work up (Fig. 2A), and a right adrenalectomy was done simultaneously with the mastectomy.
Breast tumor pathology confirmed stage IIB invasive ductal carcinoma (T2pN1M0) (Fig. 1B), and the tumor was negative for estrogen receptor, positive for progesterone receptor, and negative for HER-2 overexpression. The 5.4×3.7-cm-sized adrenal mass was confirmed as diffuse large B-cell lymphoma (stage IA) (Fig. 2B). After the operation, she received chemotherapy with a CHOP regimen for four cycles. Adjuvant radiotherapy was applied to the left breast, left chest wall, and right adrenalectomy site. The patient continued tamoxifen from 2006 to 2010, but was lost to follow-up.
In 2011, the patient visited the hospital with abdominal discomfort. Abdominal computed tomography scan showed massive ascites with peritoneal thickening (Fig. 3A). Cytologic analysis for ascitic fluid revealed clusters of adenocarcinoma cells. Thus, she underwent both salpingooophorectomy, and pathology confirmed poorly differentiated, bilateral ovarian papillary adenocarcinoma (stage IV) (Fig. 3B). She received chemotherapy with docetaxel (60 mg/m2) and carboplatin (area under the curve, 6) every three weeks, and achieved a complete remission after six cycles of treatment. However, about six months later, she was referred to Korea University Anam Hospital for the management of recurring ovarian cancer. With the second line chemotherapy using gemcitabine and carboplatin, she is in complete remission as of July 2012.
Since the patient revealed that her younger sister was also diagnosed with breast cancer at age 40, genomic analysis for BRCA1 and BRCA2mutations were performed (Table 1). The genomic analysis demonstrated a frameshift mutation in the BRCA1 gene: 277_279delinsCC (Phe93fs), a novel BRCA1 mutation never reported (Fig. 4). There was no mutation detected for the BRCA2 gene. Genomic analyses for other family members were also recommended.


The BRCA1 mutation plays a significant role in breast and ovarian cancers. Most previous studies on BRCA1 were carried out in women of European ethnicities. Because of the increasing incidence and early age onset of breast cancer in Asian women, studies to determine the prevalence and penetrance of BRCA1 and BRCA2 mutation in Asian populations are under way in many Asian countries including Korea [8-10].
A study of 21 Korean hereditary breast/ovarian cancer families identified five deleterious mutations in the BRCA1 gene; two frameshift and three non-sense mutations, without polymorphisms or unclassified variants [10]. Frameshift mutations were 4159delGA and 5221delTG, which produced a truncated protein signal at codons 1354 and 1714. Three non-sense mutations were 3459G>T (E1114X), 4014C>T (Q1299X), and 5563G>A (W1815X).
An interim report of the Korean Hereditary Breast Cancer (KOHBRA) study was recently published [11,12]. The investigators of the KOHBRA study prospectively estimated the prevalence of BRCA mutations among Korean breast cancer patients with high risk for genetic changes. Among 853 probands, 167 mutation (19.6%) carriers were identified. The prevalence of the BRCA mutation was 24.8% for breast cancer patients with a familial history of breast/ovarian cancer and 11.3% for patients with early-onset (< 35 years) breast cancer without a familial history. They identified 33 types of BRCA1 mutations in 68 cases. The most frequent mutations in BRCA1 gene were 509C>A and 5615_5625del11insA, where each was found 11 times.
In our case, a frameshift mutation in the BRCA1 gene: 277_279delinsCC (Phe93fs) was noted. This novel BRCA1 mutation is not reported in the literature. The patient’s breast cancer and subsequent ovarian cancer and her sister’s early breast cancer might be affected by this genetic change. This novel BRCA1 mutation is thought to be related to hereditary breast/ovarian cancer. Of note, our patient exhibited simultaneous diffuse large B-cell lymphoma when she was diagnosed with breast cancer. Unlike the relationship between BRCA1 mutation and breast or ovarian cancers, the role of BRCA in the pathogenesis of malignant lymphoma has not been established. However, there are several studies supporting the hypothesis that BRCA1 mutation affects the development of hematologic malignancies through defective DNA repair pathways. In a meta-analysis [7], there was a large increase in the risk of hematologic malignancies in patients with mutant genes in the BRCA pathway; mantle cell lymphoma, acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and prolymphocytic leukemia. BRCA1 deficiency was strongly associated with both de novo and therapy related acute myeloid leukemia in the study. Some epidemiologic studies [13,14] also found increased risks for leukemia/lymphoma in identified BRCA1 or BRCA2 mutation carriers. Moreover, recent study on polymorphisms in DNA repair pathways reported increased risk of diffuse large B-cell lymphoma in BRCA1 mutant patients [15].
These data suggest that a family history of hematologic malignancies, in addition to breast/ovarian cancers, could be used to determine eligibility for mutation testing of BRCA1/BRCA2 in breast cancer patients. The significance of BRCA1 mutation in the pathogenesis of malignant lymphoma and other hematologic malignancies should be further investigated.


Conflict of interest relevant to this article was not reported.

Fig. 1.
Radiologic and histologic features of the tumors. (A) The medial lateral oblique mammogram of the left breast shows 2×1.7-cm-sized oval shaped isodense mass with partially obscured margin at upper outer quadrant and 3.4×2.3-cm-sized enlarged axillary lymph node with loss of radiolucent fatty hilum at left axilla. (B) Invasive ductal carcinoma of breast (nuclear grade 2, histologic grade 2) reveals irregular infiltrative nests of tumor cells (H&E staining, ×200).
Fig. 2.
Abdomen computed tomography shows well defined homogeneously hypodense 5.4×3.7-cm-sized mass in right adrenal gland (A), and diffuse large B-cell lymphoma of adrenal gland shows diffuse proliferation of large atypical lymphoid cells with vesicular nuclei and multiple prominent nucleoli (B) (H&E staining, ×400).
Fig. 3.
Abdomen computed tomography shows massive ascites with peritoneal thickening (A) and serous carcinoma of ovary reveals infiltrative tumor nests with papillary features (B) (H&E staining, ×200).
Fig. 4.
Genomic analysis demonstrated frameshift mutation in BRCA1 gene: 277_279delinsCC (Phe93fs).
Table 1.
Genomic analysis for BRCA1 and BRCA2 mutations
Gene Exon Nucleotide change Amino acid change Zygosity Mutation type Mutation effect
BRCA1 6 277_279delinsCC Phe93fs Hetero FS NR
11 2082C>T Ser694Ser Hetero Syn P
11 2311T>C Leu771Leu Hetero Syn P
11 2612C>T Pro871Leu Hetero MS P
11 3113A>G Glu1038Gly Hetero MS P
11 3548A>G Lys1183Arg Hetero MS P
13 4308T>C Ser1436Ser Hetero Syn P
16 4837A>G Ser1613Gly Hetero MS P
BRCA2 2 (5' UTR) -26G>A - Hetero IVS P
10 1114C>A His372Asn Homo MS P
10 1176C>T Ala392Ala Hetero Syn P
11 3396A>G Lys1132Lys Hetero Syn P
11 3807T>C Val1269Val Hetero Syn P
14 7242A>G Ser2414Ser Hetero Syn P
17 (Int16) 7806-14T>C - Hetero IVS P

FS, frameshift mutation; NR, not reported; Syn, synonymous; P, polymorphism; MS, missense mutation; UTR, untranslated region; IVS, intervening sequence.


1. Ko SS; Korean Breast Cancer Society. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol. 2008;98:318–23.
crossref pmid
2. Robson ME, Boyd J, Borgen PI, Cody HS 3rd. Hereditary breast cancer. Curr Probl Surg. 2001;38:387–480.
crossref pmid
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.
crossref pmid
4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92.
crossref pmid
5. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265–71.
crossref pmid pmc
6. Kerr P, Ashworth A. New complexities for BRCA1 and BRCA2. Curr Biol. 2001;11:R668–76.
crossref pmid
7. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer. 2007;7:152.
crossref pmid pmc
8. Ahn SH, Hwang UK, Kwak BS, Yoon HS, Ku BK, Kang HJ, et al. Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci. 2004;19:269–74.
crossref pmid pmc
9. Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat. 2004;88:177–86.
crossref pmid
10. Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat. 2002;19:307–8.
11. Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, et al. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Hum Mutat. 2002;20:235.
12. Han SA, Park SK, Ahn SH, Lee MH, Noh DY, Kim LS, et al. The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. Clin Oncol (R Coll Radiol). 2011;23:434–41.
crossref pmid
13. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–10.
crossref pmid pmc
14. Shih HA, Nathanson KL, Seal S, Collins N, Stratton MR, Rebbeck TR, et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res. 2000;6:4259–64.
15. Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, et al. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Am J Hematol. 2013;88:606–11.
crossref pmid pmc
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community